Regeneron beats fourth-quarter revenue estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Regeneron (REGN) jumps on robust Q4 earnings
February 2, 2024 7:32 AM ESTShares of Regeneron Pharmaceuticals (NASDAQ: REGN) jumped more than 5% in pre-market trading Friday after the pharma company posted better-than-anticipated Q4 earnings.
Regeneron reported adjusted earnings per share (EPS) of $11.86 for the fourth quarter, beating the consensus projection of $10.62. Revenue came in at $3.43 billion,... More
